Search

Your search keyword '"Pedrosa, Marcos"' showing total 78 results

Search Constraints

Start Over You searched for: Author "Pedrosa, Marcos" Remove constraint Author: "Pedrosa, Marcos" Database Unpaywall Remove constraint Database: Unpaywall
78 results on '"Pedrosa, Marcos"'

Search Results

2. Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

4. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study

7. Magnetic resonance elastography (MRE) demonstrate the strongest correlation with digital pathology and NASH CRN fibrosis assessments, compared to transient elastography and other assessed non-invasive tests (NITs)

8. Longitudinal ALT trajectories are generally stable among patients with non-alcoholic fatty liver disease (NAFLD): an investigation using artificial recurrent neural networks

9. Second harmonic generation microscopy can quantify and subclassify early stages of NASH fibrosis progression: data from a screen-failure cohort of a NASH phase 2 study

11. 1055-P: The Machine Learning Prediction Model NASHmap Identifies Higher Insulin Resistance in Type 2 Diabetes Mellitus (T2DM) Patients at Risk for Nonalcoholic Steatohepatitis (NASH)

14. Lead Authors and Contributors

17. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial

18. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis

19. Implementation of the ECHO® telementoring model for the treatment of patients with hepatitis C

20. Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents

21. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents

22. Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders

23. Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database

26. Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir +/-Ribavirin in Patients Receiving Concomitant Acid-Reducing Agents in Phase 3 Trials

27. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

28. 1014 Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks After Treatment With Ombitasvir/Paritaprevir/R, Dasabuvir and Ribavirin in HCV Genotype 1 Patients With Cirrhosis

29. Management of Hemoglobin Decrease in Patients Treated With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients

30. Safety Comparison of 12- And 24-Week Treatments in HCV Genotype 1-Infected Patients With Cirrhosis: Results From Turquoise-II

31. Low Incidence of Hyperbilirubinemia Events With ABT-450/r-Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype-1 Infected Patients

32. Normalization of Liver-Related Laboratory Parameters in HCV Genotype 1-Infected Patients With Cirrhosis After Treatment With ABT-450/R/Ombitasvir, Dasabuvir and Ribavirin

34. Mo1059 Interim Analysis of HCC Screening and Survival in 1131 Veterans Diagnosed With HCC From 2008-2010

35. Mo1036 Development and Validation of a Virtual Child-Turcotte-Pugh Score to Assess Liver Disease Severity in an Administrative Healthcare Database

36. Endoluminal bariatric techniques

38. Sphincter of Oddi manometry

40. Drug-eluting/biodegradable stents

41. Enteral stents

42. GI endoscopes

43. Devices to improve colon polyp detection

44. Enhanced ultrasound imaging

45. Endoscopic simulators

46. Autofluorescence imaging

47. Computer-assisted personalized sedation

48. U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for “Difficult-to-Treat” HCV Genotype 1 Patients

49. Automated endoscope reprocessors

50. Endoscopic tattooing

Catalog

Books, media, physical & digital resources